Acceptance and practicability of a visual communication tool in smoking cessation counselling: a randomised controlled trial

*Stefan Neuner-Jehle1,4, Marianne I Knecht1, Claudia Stey-Steurer1,2,3, Oliver Senn1,2

1 Institute of General Practice and Health Services Research, University of Zürich, Switzerland
2 Medical Practice, Zürich, Switzerland
3 Medix HMO, Switzerland
4 Medical Practice, Zug, Switzerland

Originally received 22nd March 2013; resubmitted 18th June 2013; revised 3rd July 2013; further revision 5th July 2013; accepted 5th July 2013; online 7th October 2013

Abstract

Background: Smoking cessation advice is important for reducing the worldwide burden of disease resulting from tobacco smoking. Appropriate risk communication formats improve the success of counselling interventions in primary care.

Aims: To test the feasibility and acceptance of a smoking cessation counselling tool with different cardiovascular risk communication formats including graphs, in comparison with the International Primary Care Respiratory Group (IPCRG) ‘quit smoking assistance’ tool.

Methods: GPs were randomised into an intervention group (using our communication tool in addition to the IPCRG sheet) and a control group (using the IPCRG sheet only). We asked participants for socioeconomic data, smoking patterns, understanding of information, motivation, acceptance and feasibility, and measured the duration and frequency of counselling sessions.

Results: Twenty-five GPs performed 2.8 counselling sessions per month in the intervention group and 1.7 in the control group (p=0.3) with 114 patients. The median duration of a session was 10 mins (control group 11 mins, p=0.09 for difference). Median patients’ motivation for smoking cessation was 7 on a 10-point visual analogue scale with no significant difference before and after the intervention (p=0.2) or between groups (p=0.15 after the intervention). Median patients’ ratings of motivation, self-confidence, understanding of information, and satisfaction with the counselling were 3–5 on a 5-point Likert scale, similar to GPs’ ratings of acceptance and feasibility, with no significant difference between groups.

Conclusions: Among Swiss GPs and patients, both our innovative communication tool and the IPCRG tool were well accepted and both merit further dissemination and application in research.

© 2013 Primary Care Respiratory Society UK. All rights reserved.

Keywords risk communication, motivational interviewing, tobacco smoking cessation, short intervention, family medicine

Introduction

Tobacco smoking is a significant public health problem. About half of all persistent cigarette smokers are killed by their habit – a quarter while still in middle age – with an estimated mortality worldwide of 5,000,000 per year.4 According to the World Health Organization, smoking is the leading preventable cause of death worldwide.5 Compared with non-smokers, the relative risk of a smoker developing cardiovascular disease (CVD) is 1.6–3.0, of suffering a stroke is 1.8–4.8, and of developing lung or oropharyngeal cancer is 17.8–22.3, dependent on age and gender.6 However, the incidence (absolute risk) of malignant disease due to smoking is considerably lower than that of CVD as a potential long-term consequence of smoking.
In a recent survey in Switzerland the proportion of smokers in the population was 27%, similar to the last decade.1 Half of the smokers who consider quitting are either in a contemplation state or in a preparation state according to the transtheoretical model (TTM) of changing behaviour.5,6 In this process of reconsidering, motivation and self-efficacy are independent predictors of success.7 As the majority of Swiss smokers (84%) discussed smoking cessation issues with their general practitioners (GPs),8 GPs are important key players in the effort to reduce the proportion of smokers in a population. A short smoking cessation intervention from the GP based on the individual smoker's motivational state helps patients to quit and is therefore an important and relevant method of reducing the hazards associated with smoking.

In patient counselling, communication tools (particularly visual aids) and motivational interviewing techniques improve the success of interventions aimed at behaviour change.9,11 We therefore developed a smoking cessation counselling tool which integrates visual aids and facilitates motivational interviewing techniques. Based on the International Primary Care Respiratory Group (IPCRG) ‘quit smoking assistance’ tool and the counselling process,13 we added some relevant risk information about smoking. To translate CVD risks, we used a combination of communication formats (verbal, numerical, visual) and focused on the benefits to the patient (risk reduction) of smoking cessation. The IPCRG tool was used as the reference standard and we hypothesised that our tool is not inferior to the IPCRG tool with regard to feasibility and acceptance.

Methods

Development of the tool: choice of outcome (risk) to communicate

We chose CVD morbidity as the main risk communication issue for our tool in order to achieve maximal motivation. We calculated the absolute 10-year risk for cardiovascular events for smokers aged 35–65 years versus non-smokers of the same age using the risk calculator of the Swiss Task Force on Lipids and Atherosclerosis (www.agla.ch),14 which uses the database of the PROCAM cohort.15 Risk calculation by this tool requires age, gender, menopausal state, total serum cholesterol, serum HDL, serum triglycerides, diabetes, and family history. Our intention was to perform the counselling tool as a short intervention and as time-sparingly as possible. On the other hand, we wanted to perform individualised counselling based on the individual risk situation of each patient. Therefore, in order to avoid time-consuming data sampling from patients, we assumed gender-specific average values for most of the required cardiovascular risk factors based on the representative population-based Swiss cohort study SAPALDIA.16 Thus, GPs only had to define gender, age, and smoking state of the patients to assess the individualised cardiovascular risk, which was possible to do within a few seconds (see Appendix 1, available online at www.thepcrj.org).

In our tool, risks are shown numerically with absolute percentages, relative percentages and natural frequencies, and visually with colour-coded bar charts (see Appendix 2, available online at www.thepcrj.org). Additionally, the age-related cardiovascular risk of a non-smoker with the equivalent risk (organ age risk communication format, analogous to the lung age concept).17 In order to standardise the ‘usual’ counselling interventions for tobacco smoking cessation, all participating GPs used the recommended Opinion Sheet for smoking cessation of the IPCRG13 (see Appendix 3, available online at www.thepcrj.org) which is using motivational interviewing techniques.

Study protocol

The 27 participating GPs were randomised into an intervention group using our communication tool in addition to the IPCRG sheet, and a control group using the IPCRG sheet only. All study GPs underwent a group instruction. After a run-in period of two months to assess the frequency of usual counselling activity, the study period was six months. In each practice the GPs included up to 10 consecutive smokers aged 20–80 years. Exclusion criteria were a short life expectancy (<10 years), cognitive impairment, or any acute disease.

### Table 1. Baseline characteristics

| Characteristic | Median | IQR | Number | % of cases |
|----------------|--------|-----|--------|------------|
| **Physician characteristics** (n=27*) | | | | |
| Age, years | 48 | 43-55 | | |
| Experience as a GP, years | 10 | 4-19 | | |
| Workload, percentage (100%=5 days working/week) | 100 | 60-100 | | |
| Sex, males | 14 | | 52.9 |
| Practice type, solo | 9 | | 33.3 |
| No. of patients counselled per GP | 4 | | 2-7 |
| **Patient characteristics** (n=114) | | | | |
| Age, years | 47 | 33-57 | | |
| Sex, male | 60 | | 50.9 |
| Education level | | | | |
| primary | 12 | | 10.2 |
| secondary | 67 | | 56.8 |
| high school | 11 | | 9.3 |
| academic | 28 | | 23.7 |
| Age at the begin of smoking, years | 17 | 15-20 | | |
| Duration of smoking, years | 29 | 15-38 | | |
| Cigarettes per day | | | | |
| 1-5 | 4 | | 3.4 |
| 6-10 | 23 | | 19.5 |
| 11-15 | 18 | | 15.3 |
| 16-20 | 39 | | 33.1 |
| 21-25 | 18 | | 15.3 |
| >25 | 16 | | 13.6 |
| No attempts to quit | 74 | | 64.4 |
| Partner smoking (n with partner=67) | 31 | | 46.3 |

*Two GPs did not perform any counselling session.
Measurements
Patient data on socioeconomics, smoking history, smoking patterns, comprehensiveness of the information, satisfaction, self-confidence, acceptance, and feasibility were collected by a questionnaire using a 5-point Likert scale. Patients rated their motivation before and after the intervention on a 10-point numerical visual analogue scale (VAS). GPs measured counselling duration and frequency as a proxy for acceptance and were asked about their estimates of acceptance and practicability of the tool by a short questionnaire.

Statistics
We defined a difference in counselling frequency between the intervention and control groups of ≤ 20% as suggesting non-inferiority of the tool compared with usual care. Data are presented as median (IQR) and frequencies. Patient and counselling characteristics were compared between the intervention and control groups using Wilcoxon tests. In addition, a modified Wilcoxon rank sum test was applied to account for the potential cluster dependence at the GP level. A two-sided alpha level of 0.05 was assumed to indicate significance. The analyses were performed using Stata® Version 12.1 (Stata Corporation, College Station, Texas, USA; www.stata.com).

All patients gave written informed consent and the study was approved by the local ethics committee of Zurich.

Results
The characteristics of the GPs and patients are shown in Table 1. On average (medians), GPs had 10 years’ practice experience; two-thirds of them were working in group practices. The average patient had been a smoker since the age of 17 and for almost 30 years. One-third of patients had not tried to quit smoking before and half of the patients had partners who smoked. The prevalence of comorbidities in our study population was equal to the average Swiss practice population (data not shown).

Detailed group comparisons of counselling and tool characteristics are shown in Table 2. During the 6-month study period, 25 GPs performed 2.8 (IQR 1.7–4.2) counselling sessions per month in the intervention group and 1.7 (IQR 1.3–3.3) in the control group (p=0.3), with a total of 114 patients. Compared with the run-in period, fewer counselling sessions were performed in both groups (43.1% fewer in the intervention group and 40.0% fewer in the control group), resulting in a median (IQR) difference in change between the groups of −1.6% (−39.7% to 40.0%), p=1.0; Table 2). The median duration of a counselling session was similar in both groups (10 mins in the intervention group and 11 mins in the control group, p=0.09); 51% of counselling sessions took less than 10 mins. GPs’ ratings on practicability and usefulness were high for both tools (median of 4 on a 5-point Likert scale in the intervention group and 3 in the control group, p=0.13 and p=0.55, respectively). Patients’ motivation for smoking cessation was already high before the intervention (median 7 on a 10-point VAS) with no significant difference after the intervention (p=0.20) or between groups (p=0.73 and p=0.15 before and after the intervention, respectively). Patients’ ratings of the increase in motivation, self-confidence, comprehensiveness of the information, and satisfaction with the tool were also high (median 4 on a 5-point Likert scale).

Table 2. Comparisons of counselling and tool characteristics between groups. Results are based on 25 GPs (15 controls) and 114 counselling sessions (67 controls)

| Counselling and tool characteristics | Intervention Median (IQR) | Control Median (IQR) | p Value |
|-------------------------------------|--------------------------|----------------------|---------|
| Number of counselling sessions, per month | 2.8 (1.7-4.2) | 1.7 (1.3-3.3) | 0.30 |
| Number of counselling sessions in the run-in study period, per month | 5.5 (2.3-6.0) | 4.0 (2.5-6.0) | 0.72 |
| Change in number of counselling sessions from the run-in period to study period, per month | –1.9 (73.2;0.3) | –1.3 (–2.7;0.5) | 0.74 |
| Duration of counseling sessions, min | 10 (7-12) | 11 (8-17) | 0.09 |
| *Practicability, rated by GP | 4 (3-4) | 3 (2-4) | 0.13 |
| *Usefulness, rated by GP | 4 (3-4) | 3 (2-4) | 0.55 |
| †Patients’ motivation for smoking cessation, rated by patients: | | | |
| Before intervention | 7 (5-8) | 7 (5-8) | 0.73 |
| After intervention | 7 (5-8) | 7 (5-9) | 0.15 |
| Difference before and after intervention | 0 (0-0) | 0 (0-1) | 0.20 |
| *Patients’ increase in motivation, rated by patients | 4 (3-4) | 4 (3-5) | 0.26 |
| *Self-confidence, rated by patients | 3 (3-4) | 4 (3-4) | 0.42 |
| *Understanding of information | 5 (4-5) | 5 (5-5) | 0.35 |
| *Satisfaction with counselling | 5 (4-5) | 5 (5-5) | 0.57 |
| *Understanding of the tool | 4 (4-5) | - | |
| †Patients’ increase in motivation by the tool, rated by patients | 4 (3-4) | - | |

*Five-point Likert scale from 1 (denied) to 5 (highly approved).
†VAS from 1 (“I don’t want to quit smoking at all”) to 10 (“I want to quit smoking by all means”).
counselling were generally high (medians 3–5 on a 5-point Likert scale). In clustered data group comparisons using Wilcoxon rank sum tests, counselling time and patient ratings remained unchanged between groups (data not shown). With regard to the visual intervention tool, comprehensiveness and increase in motivation for smoking cessation due to the tool were both rated highly (medians of 4 on a 5-point Likert scale).

**Discussion**

**Main findings**

Our main finding is that adding a visual tool with a pictorial risk message as proposed by our group is not inferior to the usual smoking cessation IPCRG tool in terms of acceptance and feasibility. In fact, the majority of GPs rated both counselling tools as equally practicable and useful. No significant differences were seen between the intervention and control groups with regard to the patients’ estimates of increased motivation, self-confidence, comprehensiveness of the information, and satisfaction. Most of the counselling activities with the pictorial intervention tool were performed within 10 mins, with no significant difference in the duration of counselling compared with the control group. This underlines the feasibility of the tool, fulfilling the criteria of a short-term intervention.

The motivation level for smoking cessation was surprisingly high (median 7 points on a 10-point VAS), which could partially be due to selection bias at the patient level. The increase in motivation resulting from the counselling was not consistent: the item about self-estimation of increased motivation was mostly answered positively whereas the VAS measurement before and after counselling did not show a significant difference. A possible explanation is the short time between the two measurements: change of motivation as a basis for change of behaviour is often an iterative process over a long period. It is important to note that neither of the two communication tools decreased motivation in patients.

The decrease in counselling frequency during the study period compared with the run-in period is difficult to explain. Feedback from the study GPs suggests two main reasons: (1) a recall effect (the longer time since the instruction was given, the less alert were GPs about recruiting patients); and (2) many study GPs claimed a higher workload and lack of time during the study period in comparison with the run-in period. However, the decrease in counselling frequency was not significantly different between the intervention and control groups, so our tool was not the cause for less counselling activity.

Because a sharpened awareness of developing CVD can function as a strong motivator for behaviour change, the concept of how to communicate individualised risks for smokers versus non-smokers is highly relevant for fostering smoking cessation. We chose to communicate cardiovascular risks visually rather than respiratory risks because the absolute CVD risks (incidence) are higher than the respiratory risks, reflecting an even higher impact of the total burden of smoking-associated diseases on a patient as well as at the population level. Furthermore, the systemic effects of smoking do not only affect the respiratory system, but also the cardiovascular and other symptoms. The epidemiological evidence linking chronic obstructive pulmonary disease (COPD), for example, and cardiovascular morbidity and mortality is strong: patients with COPD have a 2–3-fold increase in the risk of cardiovascular events including death. In individuals with severe airways obstruction (forced expiratory volume in one second (FEV1) <50% of predicted), the leading causes of death are cardiovascular in nature. For every 10% decrease in FEV1, cardiovascular mortality increases by about 28% and non-fatal coronary events increase by about 20% in patients with mild to moderate COPD.

In our tool we emphasised the communication of relative risks (known to enhance the motivation to avoid risk) and present it numerically and visually. To minimise the risk of manipulation of patients with the risk format, we combined information about relative risk with data on the absolute risk of a smoker. In order to facilitate decisions, we offer a comparison with a healthy (non-smoking) reference subject. The communication of the organ (heart) age of a current smoker versus a non-smoker is another way of creating motivation by comparison of two options. Thus, using risk communication at the state of the art level results in positive effects in smoking cessation.

While calculating the relative risks of smokers versus non-smokers in the age group 35–65 years based on the data of a middle European cohort (PROCAM), we found an identical relative risk of 2 (or nearly 2) as reported from other calculators based on the Framingham cohort. Recently, the SCORE risk charts – which are also based on the Framingham cohort – started to communicate this relative risk of smokers versus non-smokers in addition to information on the absolute 10-year risk of a lethal cardiovascular event in the charts.

**Strengths and limitations of this study**

To our knowledge, this is the first randomised controlled trial (RCT) using the IPCRG smoking cessation tool as a ‘usual care’ standard. Moreover, the tool we developed is innovative and integrative in putting modern and evidence-based risk communication recommendations into daily practice.

Our study took place in one single region of Switzerland and with a relatively small number of GPs, so the results are not generalisable without restrictions. Most of our outcomes were self-estimates and not clinical outcomes, as we had neither the intention nor the means to do a RCT of the clinical effects of the intervention but, rather, wanted to test our approach and its acceptance and feasibility. As the focus of the current study was the feasibility and acceptability of the novel counselling tool, a proper *a priori* sample size calculation was not possible due to the lack of reliable *a priori* assumptions. However, based on the 114 counselling sessions in our study, there was 80% power to detect a minimal one-sided difference of 23% (alpha levels=0.05), which almost meets the *a priori* non-inferiority level postulated to be clinically relevant (difference of >20%).

We cannot exclude a selection bias due to the recruitment procedure of GPs and patients. GPs with a higher motivation for counselling activities in the field of smoking cessation might have been more prone to agree to participate and patients willing to participate might have been more motivated to start counselling than...
those who declined to participate. The high ratings of motivation (preparation stage of the TTM model) for a change at baseline might be an indicator of a possible bias. However, there was no significant difference between the intervention and control groups. We think the possible selection bias has only a small – if any – impact on our acceptance and feasibility results.

**Interpretation of findings in relation to previously published work**

Our findings encourage the use of both instruments in smoking cessation counselling. The IPCRG tool seems to be a well-accepted and feasible tool for short-term intervention smoking cessation counselling in Swiss primary care and merits further dissemination. Our additional tool fostering visual risk communication in order to increase motivation of smokers to quit is equally well accepted and feasible and might be an important add-on to the IPCRG tool.

The high level of acceptance of our tool may be due to the mixed communication formats we used – especially the focus on relative risks and visual elements – both of which were preferred by general practice patients. With regard to efficacy, the additional use of information about organ age (in our tool, heart age) is a promising interest in relation to this article.

**Implications for future research, policy and practice**

Considering the immense impact of smoking cessation on patients’ health and healthcare resources, it is of utmost importance to support and optimise smoking cessation counselling in primary care. Based on our results, we plan to carry out a RCT to test whether our visual risk communication tool has an additional effect on smoking cessation rates compared with the usual short intervention counselling, and whether the combination of our pictorial tool with the IPCRG tool is superior to the IPCRG tool alone.

**Conclusions**

In Swiss primary care, the feasibility and acceptability of both our visual smoking cessation communication tool and the IPCRG tool were equally high. Both merit further dissemination and clinical use as well as application in research.

**References**

1. Center for Disease Control (CDC), Office on Smoking and Health. Data and statistics. http://www.cdc.gov/tobacco/data_statistics/index.htm
2. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005;142:233-9.
3. D’Ol D, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking. 50 years observation on male British doctors. BMJ 1994;309:901-11. http://dx.doi.org/10.1136/bmj.309.6959.901
4. Jha P, Chaloupka FJ, Corraro M, Jacob B. Reducing the burden of smoking worldwide: effectiveness of interventions and their coverage. Drug Alcohol Rev 2006;25(6):597-609. http://dx.doi.org/10.1080/09595230600944511
5. Tabakmonitoring Schweiz. http://www.tabakmonitoring.ch
6. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 1983;51:390-5. http://dx.doi.org/10.1037/0022-006X.51.3.390
7. Haug S, Meyer C, Ulbricht S, et al. Predictors and moderators of outcome in different brief interventions for smoking cessation in general medical practice. Patient Educ Couns 2010;78:57-64. http://dx.doi.org/10.1016/jpec.2009.07.005
8. Stead LF, Bergon G, Lancaster T. Physician advice for smoking cessation (Review). The Cochrane Library 2008,(4):CD001654
9. Hil S, Spink J, Caddel D, et al. Absolute risk representation in cardiovascular disease prevention: comprehension and preferences of health care consumers and general practitioners involved in a focus group study. BMC Public Health 2010;10:108. http://dx.doi.org/10.1186/1471-2458-10-108
10. Lipkus IM. Numeric, verbal and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making 2007;27:696-713. http://dx.doi.org/10.1111/j.1547-1569.2007.00627.x
11. Goodyear-Smith F, Kenealy T, Wells S, Aroll B, Horshurg M. Patients’ preference for ways to communicate benefits of cardiovascular medication. Ann Fam Med 2011;9:121-7. http://dx.doi.org/10.1370/afm.1193
12. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598-600. http://dx.doi.org/10.1136/bmj.39503.582396.25
13. International Primary Care Respiratory Group. Helping patients quit smoking: brief interventions for healthcare professionals. http://www.thepcrj.org/resources
14. Battagly E, Noseda G, Giesen W. Atheroskelereose-Prävention. Verlag Hans Huber, Hogrefe AG, Bern, 2007.
15. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest 2007;37(12):925-32. http://dx.doi.org/10.1111/j.1365-2362.2007.01888.x
16. Achermann-Liebrich U, Kuna-Dibbert B, Probst-Hensch N, et al., for the SAPALDIA team. Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991-2003: methods and characterization of partizipants. Soz Praventivmed 2005;50:233-63. http://dx.doi.org/10.1007/s00038-005-4075-5
17. Rosner B, Glynn RJ, Lee MLT. Extension of the rank sum test for clustered data: two-group comparisons with group membership defined at the subunit level. Biometrics 2006;62:1251-9. http://dx.doi.org/10.1111/j.1541-0420.2006.00582.x
18. Galbraith EM, Mehta PK, Vedelar E, Vaccarino V, Wenger NK. Women and heart disease: knowledge, worry, and motivation. J Womens Health 2011;20(10):1529-34. http://dx.doi.org/10.1089/jwh.2010.2356
19. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16(1):63-70. http://dx.doi.org/10.1016/j.annepidem.2005.04.008
20. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28(5):1245-57. http://dx.doi.org/10.1183/09031936.0303805
21. Sin DD, Man PSF. Chronic obstructive pulmonary disease is a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2(6):11. http://dx.doi.org/10.1513/pats.200404-032MS
22. European Society of Cardiology. The SCORE risk charts. http://www.escardio.org/communities/EACPR/toolbox
**Appendix 1. Communication aid for GPs: Calculation of absolute risks and organ age in smokers versus non-smokers**

**What does your patient win by quitting smoking?**

The risk of the patient to suffer a heart attack or stroke in the next 10 years time is:

| as a woman | as a man |
|------------|---------|
| age        | 10-y-risk as | 10-y-risk as | age        | 10-y-risk as | 10-y-risk as |
|            | a smoker    | a non-smoker |            | a smoker    | a non-smoker |
| ≥ 65       | 10.6        | 5.7          | ≥ 65       | 21.6        | 12.2         |
| 64         | 9.6         | 5.2          | 64         | 19.8        | 11.3         |
| 63         | 8.7         | 4.7          | 63         | 18.1        | 10.1         |
| 62         | 7.8         | 4.2          | 62         | 16.6        | 9.2          |
| 61         | 7.2         | 3.8          | 61         | 15.2        | 8.3          |
| 60         | 6.5         | 3.5          | 60         | 13.8        | 7.5          |
| 59         | 5.8         | 3.1          | 59         | 12.6        | 6.8          |
| 58         | 5.4         | 2.8          | 58         | 11.5        | 6.2          |
| 57         | 4.9         | 2.6          | 57         | 10.5        | 5.6          |
| 56         | 4.4         | 2.3          | 56         | 9.5         | 5.1          |
| 55         | 4.0         | 2.1          | 55         | 8.6         | 4.6          |
| 54         | 3.6         | 1.9          | 54         | 7.8         | 4.2          |
| 53         | 3.3         | 1.7          | 53         | 7.1         | 3.8          |
| 52         | 2.9         | 1.5          | 52         | 6.5         | 3.4          |
| 51         | 2.7         | 1.4          | 51         | 5.8         | 3.1          |
| 50         | 2.4         | 1.3          | 50         | 5.3         | 2.8          |
| 49         | 0.5         | 0.3          | 49         | 4.8         | 2.5          |
| 48         | 0.5         | 0.3          | 48         | 4.3         | 2.3          |
| 47         | 0.4         | 0.2          | 47         | 3.9         | 2.1          |
| 46         | 0.4         | 0.2          | 46         | 3.6         | 1.9          |
| 45         | 0.4         | 0.2          | 45         | 3.2         | 1.7          |
| 44         | 0.3         | 0.2          | 44         | 2.9         | 1.5          |
| 43         | 0.3         | 0.2          | 43         | 2.6         | 1.4          |
| 42         | 0.3         | 0.1          | 42         | 2.4         | 1.2          |
| 41         | 0.2         | 0.1          | 41         | 2.1         | 1.1          |
| 40         | 0.2         | 0.1          | 40         | 1.9         | 1.0          |
| 39         | 0.2         | 0.1          | 39         | 1.8         | 0.9          |
| 38         | 0.2         | 0.1          | 38         | 1.6         | 0.8          |
| 37         | 0.2         | 0.1          | 37         | 1.4         | 0.7          |
| 36         | 0.1         | 0.1          | 36         | 1.3         | 0.7          |
| ≤ 35       | 0.1         | 0.1          | ≤ 35       | 1.2         | 0.6          |

Comments:

Blood pressure and lipids (total cholesterol, triglycerides, HDL, LDL) refer to the average values of the Swiss SAPALDIA population. Family history of early cardiovascular events was assumed to be negative for the calculation (as this is the more frequent situation compared to a positive family history). Women up to the age of 40 years were classified as premenopausal, over the age of 50 years as postmenopausal. These assumed data were entered into the AGA online cardiovascular risk calculator (www.aiub.ch/10-1.htm) utilizing the co-variates gender, age and smoker or non-smoker.

*The relative risk of smokers versus non-smokers is almost 3 in all age groups. Only in women below 30 years of age the risks for smokers and non-smokers are equal (equally low). This should be communicated in counseling, for example „The risk is not staying so low all the time; yet from the age of 37, you can lower your risk by 50% with stop smoking.”

Copyright: Institute of General Practice and Health Service Research Zürich, Switzerland
Appendix 2. Visually supported risk communication tool (intervention tool)

What do I win by quitting smoking?

**my risk**

If I continue to smoke, my risk to get a heart attack or stroke within the next 10 years is **%** (1 out of **).

**my risk as a non-smoker**

With quitting smoking right now, I lower my risk by almost 50% (from **%** to **%) compared with going on with smoking.

In my age, the risk to get a heart attack or stroke within the next 10 years is equal to the risk of a ** years old non-smoker!**

If I have elevated blood pressure, lipid (cholesterol) or blood sugar values, the risks are higher than the above mentioned values. By quitting smoking, the risk will be half in comparison to going on with smoking as well. I also lower further risks substantially, such as lung cancer or chronic bronchitis with quitting smoking.

*Copyright: Institute of General Practice and Health Service Research Zürich, Switzerland*
Appendix 3. IPCRG Opinion sheet for stop smoking (in english)

Helping patients quit smoking: brief interventions for healthcare professionals

How to help smokers quit: flowchart

Ask

Are you using tobacco in the last 12 months?

Yes - Quit in the last 12 months

Congratulations.

Ask: If they need help to remain smoke free, advise them to contact you or to seek other counseling (they have any difficulty quitting, smoking cessation diets, etc...)

Yes - Current smoker: Take brief smoking history, including number of cigarettes smoked a day, years started smoking, presence of smoking-related disease, previous quit attempts and what happened?

Use non judgmental questions such as: "How do you feel about your smoking at the moment?"

Express concern/interest and not judgment.

Are you planning to quit in the next 6 months?

No - Planning to Quit in the next 6 months

Yes - Ready to quit

ADVICE

Focus on their ambivalence, help them be motivated to quit.

Offer help by asking:

"What are the things you find most difficult about quitting smoking?"

"How do you feel if you quit?"

"How do you feel if you quit?"

"What would it take for your motivation score to increase?"

"How can I help you increase your confidence in quitting?"

ASSIST

Explore barriers to cessation.

Offer help quitting.

Refer to quit line or other counseling, refer to smoking cessation materials if patient chooses.

Hand out written material/contact numbers.

Follow up consultation or telephone contact within 6 months OR cessation to ask when you see the patient.

ARRANGE

Follow up consultant's phone calls.

Call weekly for 6 weeks then monthly.

5 As of smoking cessation: Ask, Assess, Advise, Assist, Arrange

OPINION

IPCRG OPINION 3

PRIMARY CARE RESPIRATORY JOURNAL

www.thepcj.org
### Pilot study of a smoking cessation counselling tool

#### PRIMARY CARE RESPIRATORY JOURNAL

www.thepcrj.org

---

**Appendix 4. VISTO pilot study - CONSORT 2010 checklist of information to include when reporting a randomised trial**

| Section/Topic        | Item No | Checklist item                                                                 | Reported on page No |
|----------------------|---------|---------------------------------------------------------------------------------|---------------------|
| **Title and abstract** | 1a      | Identification as a randomised trial in the title                               | 1                   |
|                      | 1b      | Structured summary of trial design, methods, results, and conclusions (if specific guidance on CONSORT is relevant) | 1                   |
| **Introduction**     | 2a      | Scientific background and explanation of rationale                              | 1,2                 |
|                      | 2b      | Specific objectives or hypothesis                                                | 2                   |
| **Methods**          | 3a      | Description of trial design (such as parallel, factorial) including allocation ratio | 2                   |
|                      | 3b      | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | not applicable     |
| **Participants**     | 4a      | Eligibility criteria for participants                                           | 2                   |
|                      | 4b      | Settings and locations where the data were collected                            | 2                   |
| **Interventions**    | 5       | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 2                   |
| **Outcomes**         | 6a      | Completely defined primary and secondary outcomes measures, including how and when they were assessed | 2                   |
|                      | 6b      | Any changes to trial outcomes after the trial commenced, with reasons           | not applicable     |
| **Sample size**      | 7a      | How sample size was determined                                                   | 2                   |
|                      | 7b      | When applicable, explanation of any interim analyses and stopping guidelines     | not applicable     |
| **Randomization**    | 8a      | Method used to generate the random allocation sequence                           | 2                   |
|                      | 8b      | Type of randomization; details of any restriction (such as blocking and block size) | 2                   |
| **Allocation concealment mechanism** | 9      | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | not applicable |
| **Implementation**   | 10      | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 2                   |
| **Blinding**         | 11a     | If done, who was blinded after assignment to interventions (for example, participants, care providers, those | not applicable |

**CONSORT 21X0 checklist**
### Appendix 4. VISTO pilot study - CONSORT 2010 checklist of information to include when reporting a randomised trial continued

| Item | Description |
|------|-------------|
| 11b  | Irrelevant, description of the similarity of interventions |
| 12a  | Statistical methods used to compare groups for primary and secondary outcomes |
| 12b  | Methods for additional analyses, such as subgroup analyses and adjusted analyses |
| 13a  | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome |
| 13b  | For each group, losses and exclusions after randomisation, together with reasons |
| 14a  | Dates defining the periods of recruitment and follow-up |
| 14b  | Why the trial ended or was stopped |
| 15   | A table showing baseline demographic and clinical characteristics for each group |
| 16   | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups |
| 17a  | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) |
| 17b  | For binary outcomes, presentation of both absolute and relative effect sizes is recommended |
| 18   | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory |
| 19   | All important harms or unintended effects in each group (for specific states see CONSORT for harms) |
| 20   | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses |
| 21   | Generalisability (external validity, applicability) of the trial findings |
| 22   | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence |
| 23   | Registration number and name of trial registry |
| 24   | Where the full trial protocol can be accessed, if available |
| 25   | Sources of funding and other support (such as supply of drugs), role of funders |

* CONSORT 2010 checklist